InvestSMART

PYC Therapeutics Limited (ASX: PYC) - Announcements

Current share price for PYC : $2.250 0.01 (0.44%)+

ASX company news and announcements for PYC Therapeutics Limited (PYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PYC Therapeutics Limited (PYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PYC Therapeutics Limited (PYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PYC Therapeutics Limited (PYC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,213 Becoming a substantial holder 18 Nov 2025 9:45AM $1.300 $2.250 risen by 73.08%
$2,213 Annual General Meeting Presentation 18 Nov 2025 9:33AM $1.300 $2.250 risen by 73.08%
$2,213 Sustained Vision Improvement in RP11 Patients 14 Nov 2025 8:19AM $1.320 $2.250 risen by 70.45%
$2,213 Board Renewal 13 Nov 2025 9:22AM $1.190 $2.250 risen by 89.08%
$2,213 Annual General Meeting - Conference Link 11 Nov 2025 8:34AM $1.185 $2.250 risen by 89.87%
$2,213 Becoming a substantial holder 7 Nov 2025 4:25PM $1.165 $2.250 risen by 93.13%
$2,213 Quarterly Activities/Appendix 4C Cash Flow Report 27 Oct 2025 9:31AM $1.195 $2.250 risen by 88.28%
$2,213 ADOA Program Initiation of Global Repeat Dose Study 21 Oct 2025 9:16AM $1.220 $2.250 risen by 84.43%
$2,213 Notice of Annual General Meeting/Proxy Form 17 Oct 2025 11:58AM $1.235 $2.250 risen by 82.19%
$2,213 PMS Program Data Supports Progression to Human Trials 13 Oct 2025 9:21AM $1.150 $2.250 risen by 95.65%
$2,213 Investor Webinar Presentation 13 Oct 2025 9:08AM $1.150 $2.250 risen by 95.65%
$2,213 ADOA Program Progressing to Multiple Dose Study 9 Oct 2025 9:33AM $1.210 $2.250 risen by 85.95%
$2,213 Investor Webinar 30 Sep 2025 9:11AM $1.030 $2.250 risen by 118.45%
$2,213 Appendix 3X and 3Z 22 Sep 2025 4:56PM $1.040 $2.250 risen by 116.35%
$2,213 Board and Management Changes 22 Sep 2025 8:32AM $0.895 $2.250 risen by 151.40%
$2,213 Correction to Trading Halt Request 19 Sep 2025 10:00AM $0.895 $2.250 risen by 151.40%
$2,213 Trading Halt 19 Sep 2025 9:26AM $0.895 $2.250 risen by 151.40%
$2,213 Change of Managing Director 17 Sep 2025 8:27AM $1.215 $2.250 risen by 85.19%
$2,213 ADOA Program - Presentation of Clinical Data at NOSA 2025 5 Sep 2025 9:03AM $1.270 $2.250 risen by 77.17%
$2,213 PKD Program - Presentation of Safety Data at ANZSN 29 Aug 2025 8:37AM $1.290 $2.250 risen by 74.42%
$2,213 PKD Program - Presentation of Safety Data at ANZSN 29 Aug 2025 8:37AM $1.290 $2.250 risen by 74.42%
$2,213 2025 Corporate Governance Statement 28 Aug 2025 5:24PM $1.290 $2.250 risen by 74.42%
$2,213 Appendix 4G 28 Aug 2025 5:22PM $1.290 $2.250 risen by 74.42%
$2,213 2025 Annual Report to Shareholders 28 Aug 2025 5:18PM $1.290 $2.250 risen by 74.42%
$2,213 Appendix 4E 28 Aug 2025 5:15PM $1.290 $2.250 risen by 74.42%

76 - 100 of 937 results

Page 4 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.